0.4347
1.57%
+0.0067
Redhill Biopharma Ltd. ADR stock is currently priced at $0.4347, with a 24-hour trading volume of 117.08K.
It has seen a +1.57% increased in the last 24 hours and a -17.97% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.428 pivot point. If it approaches the $0.4398 resistance level, significant changes may occur.
Previous Close:
$0.428
Open:
$0.43
24h Volume:
117.08K
Market Cap:
$13.70M
Revenue:
$35.75M
Net Income/Loss:
$11.57M
P/E Ratio:
-0.1142
EPS:
-3.8069
Net Cash Flow:
$-26.25M
1W Performance:
-1.74%
1M Performance:
-17.97%
6M Performance:
-8.08%
1Y Performance:
-82.11%
Redhill Biopharma Ltd. ADR Stock (RDHL) Company Profile
Name
Redhill Biopharma Ltd. ADR
Sector
Phone
972 3 541 3131
Address
21 Ha’arba’a Street, Tel Aviv
Redhill Biopharma Ltd. ADR Stock (RDHL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-31-21 | Initiated | Cantor Fitzgerald | Overweight |
May-18-21 | Initiated | H.C. Wainwright | Buy |
Sep-11-20 | Initiated | BTIG Research | Buy |
Jul-12-19 | Upgrade | WBB Securities | Buy → Strong Buy |
Mar-12-19 | Upgrade | WBB Securities | Speculative Buy → Buy |
Jan-26-18 | Initiated | Nomura | Buy |
Oct-06-17 | Initiated | Seaport Global Securities | Buy |
Oct-04-17 | Reiterated | H.C. Wainwright | Buy |
Feb-24-17 | Reiterated | FBR & Co. | Outperform |
Jul-27-16 | Reiterated | FBR Capital | Outperform |
Sep-29-15 | Initiated | Nomura | Buy |
Jul-29-15 | Reiterated | ROTH Capital | Buy |
Jun-17-15 | Reiterated | H.C. Wainwright | Buy |
Jun-15-15 | Reiterated | ROTH Capital | Buy |
View All
Redhill Biopharma Ltd. ADR Stock (RDHL) Latest News
Nasdaq Edges Lower; American Airlines Posts Upbeat Earnings
Benzinga
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
Benzinga
Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why Netflix Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Redhill Biopharma Ltd. ADR Stock (RDHL) Financials Data
Redhill Biopharma Ltd. ADR (RDHL) Revenue 2024
RDHL reported a revenue (TTM) of $35.74 million for the quarter ending June 30, 2023, a -52.42% decline year-over-year.
Redhill Biopharma Ltd. ADR (RDHL) Net Income 2024
RDHL net income (TTM) was $11.57 million for the quarter ending June 30, 2023, a +114.84% increase year-over-year.
Redhill Biopharma Ltd. ADR (RDHL) Cash Flow 2024
RDHL recorded a free cash flow (TTM) of -$26.25 million for the quarter ending June 30, 2023, a +52.11% increase year-over-year.
Redhill Biopharma Ltd. ADR (RDHL) Earnings per Share 2024
RDHL earnings per share (TTM) was -$3.8069 for the quarter ending June 30, 2023, a +94.05% growth year-over-year.
About Redhill Biopharma Ltd. ADR
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Cap:
|
Volume (24h):